Which semaglutide formulation does the compounded injection containing 1 mg semaglutide per 0.5 mL (combined with cyanocobalamin) correspond to?

This is a Compounded Semaglutide Formulation, Not FDA-Approved

Your patient is receiving a compounded semaglutide preparation that is NOT equivalent to FDA-approved Ozempic or Wegovy, and the AACE strongly advises against using such compounded alternatives. 1

Critical Safety Concerns with This Compounded Product

The label indicates "Semaglutide/Cyanocobalamin 1mg/1mg/0.5mL" - this is a compounded formulation combining semaglutide with vitamin B12 (cyanocobalamin). This poses significant safety risks:

Immediate Dosing Clarification Issues

• The concentration is 1 mg semaglutide per 0.5 mL, which means 2 mg/mL concentration
• If the patient is injecting 0.5 mL, they are receiving 1 mg of semaglutide per injection
• This dose corresponds roughly to the maintenance dose range used in FDA-approved formulations (Ozempic uses 0.5 mg or 1 mg weekly doses for diabetes; Wegovy uses up to 2.4 mg weekly for weight loss) 2, 3

Major Safety Problems with Compounded Semaglutide

Compounded semaglutide preparations have demonstrated:

• Inaccurately labeled concentrations - the actual amount may differ from what's stated 1
• Impurities, trace metals, residual solvents 1
• Neopeptides with potential immunogenicity (compounded versions use peptide synthesis, not recombinant DNA like FDA-approved products) 1
• 10-fold dosing errors leading to hospitalizations - the FDA has issued warnings about overdosing with compounded semaglutide 1, 4
• Lack of safety features present in prefilled manufactured pens 4

Documented Adverse Events

Case reports show patients receiving compounded semaglutide from vials experienced:

• Severe nausea, vomiting, and abdominal pain lasting days
• Confusion about dosing units (milliliters vs. units vs. milligrams)
• Lack of proper pharmacist counseling on administration 4

Regulatory Status

The FDA has recently placed semaglutide on the "demonstrable difficulties for compounding" list, which prohibits compounding these medications under sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act. 1

Clinical Recommendation

You should:

1. Verify the exact dose the patient is self-administering - confirm they understand they are injecting 1 mg of semaglutide if using the full 0.5 mL volume
2. Assess for dosing errors - ask specifically how they measure the dose (using syringe markings in mL, units, or mg)
3. Monitor closely for adverse effects, particularly gastrointestinal symptoms and signs of overdose
4. Transition to FDA-approved semaglutide (Ozempic for diabetes, Wegovy for obesity) as soon as feasible 1
5. Document this as a patient safety concern in the medical record

If Continuing Compounded Semaglutide Temporarily

While transitioning to FDA-approved products:

• Ensure proper injection technique and dose measurement
• Provide explicit written instructions on dose administration
• Schedule close follow-up (within 1-2 weeks)
• Counsel on gastrointestinal side effects and when to seek emergency care
• Consider slower dose titration given quality concerns

The combination with cyanocobalamin (B12) has no established clinical benefit for semaglutide therapy and appears to be a marketing strategy by compounding pharmacies. 5